Profile data is unavailable for this security.
About the company
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is developing two drug candidates: NXP800 and NXP900. NXP800 is a small molecule GCN2 activator, which is in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. NXP800 activates the GCN2 kinase inducing inhibition of cap-dependent protein translation and activation of the integrated stress response leading to cancer cell death. NXP900 is a targeted-therapy, small molecule drug candidate that inhibits the proto-oncogene c-Src (SRC) and YES1 kinases, which is undergoing a Phase 1a dose escalation study. SRC is aberrantly activated in many cancer types, including solid tumor cancers such as breast, colon, prostate, pancreatic and ovarian cancers.
- Revenue in USD (TTM)0.00
- Net income in USD-28.87m
- Incorporated2020
- Employees13.00
- LocationNuvectis Pharma Inc1 Bridge Plaza, 2nd FloorFORT LEE 07024United StatesUSA
- Phone+1 (360) 837-7232
- Fax+1 (302) 636-5454
- Websitehttps://nuvectis.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Humacyte Inc | 1.57m | -36.97m | 206.51m | 218.00 | -- | -- | -- | 131.45 | -0.2206 | -0.2206 | 0.011 | -0.0299 | 0.0152 | -- | -- | 7,206.42 | -35.84 | -41.46 | -46.28 | -45.37 | 60.53 | -- | -2,353.22 | -8,438.13 | 0.8965 | -- | 1.10 | -- | -- | -- | -34.24 | -- | -28.00 | -- |
| Neonc Technologies Holdings Inc | 59.99k | -48.88m | 208.31m | 3.00 | -- | -- | -- | 3,472.48 | -2.59 | -2.59 | 0.0032 | -0.6067 | 0.0176 | -- | -- | -- | -1,431.87 | -- | -- | -- | 33.34 | -- | -81,472.06 | -- | -- | -22.45 | -- | -- | 17.80 | -- | 20.26 | -- | -- | -- |
| Prenetics Global Ltd | 92.39m | -52.70m | 215.68m | 285.00 | -- | 0.9907 | -- | 2.33 | -3.60 | -4.02 | 6.58 | 15.43 | 0.443 | 6.38 | 22.48 | -- | -26.36 | -55.58 | -31.23 | -71.68 | 52.97 | 47.68 | -59.49 | -381.63 | 2.76 | -13.87 | 0.01 | -- | 479.76 | 7.23 | -51.06 | -- | 77.92 | -- |
| Heron Therapeutics Inc | 154.90m | -20.20m | 216.82m | 128.00 | -- | 16.30 | -- | 1.40 | -0.1205 | -0.1205 | 0.8733 | 0.0761 | 0.6335 | 0.5668 | 1.84 | 1,210,188.00 | -8.26 | -41.54 | -13.40 | -61.25 | 73.31 | 60.34 | -13.04 | -88.20 | 1.51 | -0.2662 | 0.9075 | -- | 7.36 | 11.81 | -48.71 | -- | -45.86 | -- |
| Angion Biomedica Corp | 0.00 | -45.86m | 218.62m | 32.00 | -- | 56.53 | -- | -- | -3.15 | -3.15 | 0.00 | 0.2211 | 0.00 | -- | -- | 0.00 | -137.56 | -106.87 | -179.35 | -289.86 | -- | -- | -- | -778.01 | -- | -302.49 | 0.7181 | -- | -- | -- | -47.46 | -- | -18.50 | -- |
| Context Therapeutics Inc | 0.00 | -26.44m | 218.67m | 12.00 | -- | 2.99 | -- | -- | -0.2835 | -0.2835 | 0.00 | 0.7964 | 0.00 | -- | -- | 0.00 | -31.94 | -44.73 | -33.64 | -57.02 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.52 | -- | -- | -- |
| Ovid Therapeutics Inc | 6.61m | -36.33m | 221.31m | 23.00 | -- | 2.71 | -- | 33.48 | -0.5112 | -0.5112 | 0.093 | 0.6282 | 0.0794 | -- | -- | 287,391.30 | -43.64 | -13.89 | -49.07 | -15.44 | -- | -- | -549.62 | -40.79 | -- | -- | 0.00 | -- | 44.50 | -- | 49.50 | -- | -7.98 | -- |
| Arcturus Therapeutics Holdings Inc | 97.60m | -66.71m | 224.74m | 174.00 | -- | 0.9593 | -- | 2.30 | -2.46 | -2.46 | 3.60 | 8.25 | 0.2989 | -- | 5.12 | 560,919.60 | -20.43 | -19.22 | -24.18 | -24.16 | -- | -- | -68.35 | -68.95 | -- | -- | 0.00 | -- | -8.69 | 48.93 | -172.30 | -- | -4.55 | -- |
| Voyager Therapeutics Inc | 31.32m | -126.78m | 226.29m | 172.00 | -- | 1.03 | -- | 7.23 | -2.17 | -2.17 | 0.5358 | 3.96 | 0.0877 | -- | 2.64 | 182,069.80 | -35.50 | -1.01 | -39.95 | -1.27 | -- | -- | -404.85 | -2.34 | -- | -- | 0.00 | -- | -68.00 | -5.18 | -149.12 | -- | -14.53 | -- |
| Surrozen Inc | 3.60m | -86.91m | 230.14m | 40.00 | -- | -- | -- | 63.86 | -19.76 | -19.76 | 0.6008 | -2.74 | 0.0507 | -- | 0.4882 | 90,100.00 | -122.36 | -60.48 | -134.33 | -68.26 | -- | -- | -2,411.38 | -993.19 | -- | -- | -- | -- | -- | -- | -47.68 | -- | -55.92 | -- |
| Achieve Life Sciences Inc | 0.00 | -52.35m | 230.50m | 25.00 | -- | 6.80 | -- | -- | -1.38 | -1.38 | 0.00 | 0.6365 | 0.00 | -- | -- | 0.00 | -104.74 | -95.73 | -125.36 | -142.31 | -- | -- | -- | -- | -- | -- | 0.2271 | -- | -- | -- | -33.58 | -- | -- | -- |
| Nuvectis Pharma Inc | 0.00 | -28.87m | 230.74m | 13.00 | -- | 12.15 | -- | -- | -1.31 | -1.31 | 0.00 | 0.7171 | 0.00 | -- | -- | 0.00 | -105.10 | -123.50 | -188.03 | -201.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -51.95 | -- | -- | -- |
| Inhibikase Therapeutics Inc | 0.00 | -47.66m | 230.92m | 15.00 | -- | 1.96 | -- | -- | -1.15 | -1.15 | 0.00 | 0.9745 | 0.00 | -- | -- | 0.00 | -113.51 | -56.32 | -131.71 | -65.21 | -- | -- | -- | -1,965.97 | -- | -- | 0.00 | -- | -100.00 | -- | -44.62 | -- | -- | -- |
| Alector Inc | 21.05m | -142.93m | 232.87m | 103.00 | -- | 7.60 | -- | 11.07 | -1.39 | -1.39 | 0.2043 | 0.2777 | 0.0553 | -- | -- | 204,320.40 | -37.54 | -18.23 | -50.42 | -22.68 | -- | -- | -679.16 | -100.47 | -- | -- | 0.2402 | -- | -79.07 | -0.0503 | -20.06 | -- | -61.79 | -- |
| OmniAB Inc | 21.09m | -63.67m | 249.04m | 114.00 | -- | 0.8976 | -- | 11.81 | -0.5906 | -0.5906 | 0.1956 | 1.93 | 0.0658 | -- | 6.40 | 185,035.10 | -19.86 | -- | -20.75 | -- | 27.71 | -- | -301.83 | -101.09 | 4.96 | -- | 0.00 | -- | -22.75 | 7.58 | -22.55 | -- | 49.04 | -- |
| Palisade Bio Inc | 0.00 | -11.23m | 251.82m | 8.00 | -- | 4.80 | -- | -- | -2.98 | -2.98 | 0.00 | 0.3522 | 0.00 | -- | -- | 0.00 | -137.67 | -130.84 | -221.20 | -165.85 | -- | -- | -- | -31,830.91 | -- | -1,041.55 | 0.0616 | -- | -100.00 | -- | -17.38 | -- | -- | -- |
Data as of Mar 03 2026. Currency figures normalised to Nuvectis Pharma Inc's reporting currency: US Dollar USD
14.32%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 724.57k | 2.83% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 711.52k | 2.78% |
| Iridian Asset Management LLCas of 31 Dec 2025 | 586.32k | 2.29% |
| Baldwin Wealth Partners LLCas of 31 Dec 2025 | 389.63k | 1.52% |
| Occam Crest Management LPas of 31 Dec 2025 | 380.00k | 1.48% |
| Geode Capital Management LLCas of 31 Dec 2025 | 364.02k | 1.42% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 154.67k | 0.60% |
| Susquehanna Financial Group LLLPas of 31 Dec 2025 | 134.15k | 0.52% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 115.17k | 0.45% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2025 | 107.60k | 0.42% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
